While whole genome/exome sequencing in a research setting may be used to explore the genetic basis of a phenotype it also offers the chance to opportunistically screen for additional results unrelated to the research project but relevant to the participants' future medical health (termed 'incidental findings', IFs).There is a wealth of medical and ethics literature supporting the feedback of IFs, yet there is limited empirical work offering a voice from both professional and public stakeholders directly affected by this. I will explore the current debate about sharing IFs in both a clinical and research setting and offer results from our web-based survey that has investigated the attitudes of 6,944 individuals from across 91 countries towards searching for and sharing incidental findings from genome research studies.
While whole genome/exome sequencing in a research setting may be used to explore the genetic basis of a phenotype it also offers the chance to opportunistically screen for additional results unrelated to the research project but relevant to the participants' future medical health (termed 'incidental findings', IFs).There is a wealth of medical and ethics literature supporting the feedback of IFs, yet there is limited empirical work offering a voice from both professional and public stakeholders directly affected by this. I will explore the current debate about sharing IFs in both a clinical and research setting and offer results from our web-based survey that has investigated the attitudes of 6,944 individuals from across 91 countries towards searching for and sharing incidental findings from genome research studies.
Eighty percent of participants believed that incidental findings from sequencing studies should be made available to research participants if they want them. Treatability and perceived usefulness of the data were important, with 98% personally interested in learning about life-threatening conditions that were preventable. However, only 31% of participants thought genomic researchers should actively search for incidental findings that were not relevant to their research study. Genetic health professionals held the most conservative views towards all aspects of data sharing. Ours is the largest dataset published to date on such attitudes. I will share an overview of how the debate about IFs has progressed in the United Kingdom. I will also offer information about the UK government initiative to sequence 100,000 genomes of patients in the National Health Service.
Newborn screening has been a success story for over 50 years. The early diagnosis of babies with serious, treatable disorders enables appropriate neonatal management, improved outcome, and may be life-saving. There are, however, some harms, particularly for patients with mild phenotypes who may not require any treatment. With the expansion of newborn screening to encompass more and rarer disorders this is becoming a major problem. Three examples have been chosen to illustrate mild phenotypes still not well-enough understood, what research is required and what is already ongoing to better define the need for treatment in babies with these mild forms of a disorder: the 'old' disorders of galactosaemia (Duarte/galactosemia compound heterozygote) and congenital hypothyroidism, and a newer inclusion in screening, very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD). New treatments, especially mutation-specific therapies, mean that more disorders will be considered for inclusion in screening panels. New treatments also mean that long-term follow-up of all treated patients must be incorporated in newborn screening programs. The moves towards an agreed overarching policy for newborn screening in Australia will aid attainment of these aims locally.
genes (and 100s of pseudogenes and non-coding genes). Over the past 20 years a significant effort has been put into the identification of X-chromosome disease-causing DNA sequence variation, making the X one of the best studied human chromosomes. Of the protein-coding genes ∼110 (13%) genes have been implicated (published and our unpublished data) in various forms of syndromic and non-sydromic intellectual disability. In addition to this multiple regions of the X-chromosome have been involved in intellectual disability through structural variation, including copy number variation, translocation and inversion. I will present an overview of the X-chromosome sequence variation in intellectual disability and how this summarized data is helping us to identify additional Xchromosome regions likely to be implicated (or not) in intellectual disability as well as redefining the role of known XLID loci. I will also discuss some of our most recent XLID gene discoveries. In synthesizing our and international efforts so far to identify the majority if not all intellectual disability (and clinically relevant in general) loci on the X-chromosome I will point to the remaining challenges as well as to the genome-wide relevance of the
Plenary 8 MISSING VARIANTS IN HIGH THROUGHPUT SEQUENCING: METHODS FOR THE DETECTION OF DISEASE CAUSING VARIANTS
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Next-generation sequencing (NGS) has led to an unprecedented increase in the discovery of disease causing variants. However, many family studies with strong linkage peaks remain unsolved despite repeated rounds of NGS. We describe some strategies with NGS data analysis that could lead to the discovery of a variant by incorporating familial and population data and extending the NGS analysis pipeline to look for more unusual causes of disease. We describe examples where the use of such information led to the identification of causal variants where standard filtering methods would not have succeeded or gotten to the answer in a timely manner.
Intellectual disability (ID) occurs in 2-3% of the general population and the cause remains unknown in about 50% of patients. Knowing the cause allows anticipation on associated health and behavior problems and is essential for counseling regarding recurrence risk and prognosis. The extensive genetic heterogeneity of ID requires a genome wide detection of all types of genetic variation. Microarray studies and more recently exome sequencing have demonstrated the importance of de novo copy number variations and single nucleotide variations.
The implementation of exome sequencing in our diagnostic setting in December 2011 has led to significant changes in our daily clinical genetic practice, including pre-test counseling issues, interpretation of test-results in regard to the patient's phenotype and the approach to unexpected results. In the past 2 years, over 1,000 clinical exomes have been performed, including 400 ID patientparents trios. Workflow, experiences and pitfalls from a clinician's perspective will be discussed. Furthermore, the introduction of next generation sequencing techniques has led to the identification of novel recurrent genes within our ID cohort. An overview of several recently delineated syndromes will be presented.
Finally, in a subset of 50 individuals with severe ID, in whom micro-array-based CNV analysis and whole exome sequencing were negative, we applied whole genome sequencing. Notwithstanding the extensive genetic prescreening, a conclusive genetic diagnosis could be established in 21 patients (42%). These included 8 de novo CNVs, including single exon and intraexonic deletions as well as interchromosomal duplications, 12 de novo SNVs affecting the coding region and one compound heterozygous CNV causing disease in a recessive mode. These results suggest that de novo SNVs and CNVs affecting the coding region are a major cause of severe ID.
Plenary 10 NON-INVASIVE CANCER GENOME SCANNING BY PLASMA DNA ANALYSIS Rossa W. K. Chiu
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Malignant tumors release DNA into plasma. The analysis of tumorassociated nucleic acid markers in plasma enabled the development of blood-based tests for the diagnosis, monitoring and prognostication of cancers. However, cancers are highly heterogeneous in nature. Thus, different biomarkers are required for the detection of cancers of different organs or subtypes. With the advent of nextgeneration sequencing, whereby billions of DNA fragments can be identified and quantified in each analysis run, our group asked if the cancer genome can be decoded directly from human plasma. In our recent studies (Chan et al., Clin Chem 2012; Chan et al., PNAS 2013) , we showed that copy number aberrations and methylation profiles of cancers can be detected from plasma DNA sequencing on a genome-wide manner. Because the approach detects any genomic changes that might be associated with a cancer, it can be applied to multiple cancer types. Tumor-associated genomic abnormalities were detected in plasma of patients with cancers of the liver, breast, ovary, lung, colon, nasopharynx or smooth muscles. We analysed plasma samples collected from a patient with synchronous breast and ovarian cancers. The plasma DNA profile revealed collective genetic aberrations from both the breast and ovarian cancers. These data suggest that plasma DNA sequencing is a potential tool for studying tumoral heterogeneity and may allow one to assess the total tumor burden in an individual. The long-term goal of the research is to achieve a test that could be applied for the screening and monitoring of multiple cancer types.
The development of high throughput technologies, especially next generation DNA sequencing, means that within the next 2-3 years a complete 'parts list' for human cancer will be available. Collaborative studies, particularly the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) are uncovering driver mutations present in human cancer that are detectable at the level of point mutation, changes in DNA copy number, structural variation, transcriptional change, and/or altered pattern of methylation. Genomic analysis of human cancer is shifting from individual tumor types to pan-cancer analyses of thousands of samples across histotypes, identifying processes common to anatomically distinct cancers and resulting in a reclassification of cancer. The presentation will focus on our work on ovarian cancer and cancers of known primary. For the ovarian studies, which are part of the ICGC, I will outline findings from whole genome sequence analysis of over 100 high grade serous cancer genomes. The cancer of unknown primary work is heavily translational and is aimed at improving the clinical management, both through identification of likely site of origin and use of mutational profiling to guide cancer care.
Herein we present progress in non-invasive and non-irradiating 3D facial analysis that provides deeply precise objective measurements with a view to enabling clinical unmet need in diagnosis and treatment monitoring. We focus on studies in our, and collaborating, group(s), including novel approaches to asymmetry assessment in syndromic diseases, new facial signatures of rare diseases, and treatment monitoring in metabolic and non-metabolic disorders. We also outline studies exploring the overlap between normal range and syndromic facial variation and foundation methods for converting 3D facial information to text, namely elements of morphology terms. The later may facilitate automated reporting and fusion with text mining approaches for exploring human disease biology and aiding with computer assisted diagnostics. Craniosynostosis is one of the most common craniofacial disorders encountered in clinical genetics practice. Between 30-70% of syndromic craniosynostoses are caused by mutations in hotspots in the fibroblast growth factor receptor (FGFR) genes or in the TWIST1 genes. Here we present results from molecular testing of an Australia and New Zealand cohort of 630 individuals with a diagnosis of craniosynostosis. Data were obtained by Sanger sequencing of FGFR1-3 hotspot exons and the TWIST1 gene, as well as copy number detection of TWIST1. Of the 630 probands, there were 231 who had one of 80 distinct mutations (36%). Among the 80 mutations, 17 novel sequence variants were detected in three of the four genes screened. In addition to the proband cohort there were 96 individuals who underwent predictive or prenatal testing as part of family studies. Dysmorphic features consistent with the known FGFR1-3/TWIST1-associated syndromes were predictive for mutation detection. We also show a statistically significant association between splice site mutations in FGFR2 and a clinical diagnosis of Pfeiffer syndrome, more severe clinical phenotypes associated with FGFR2 exon 10 versus exon 8 mutations, and more frequent surgical procedures in the presence of a pathogenic mutation. Although targeting gene hot spot areas for mutation analysis has been a useful strategy to maximize the success of molecular diagnosis for individuals with craniosynostosis, technological developments have allowed additional genes to be sequenced rapidly. We present the initial findings of a massively parallel sequencing gene panel in this cohort, which has extended molecular findings in mutation negative patients.
Alternative exon selection occurs both naturally, increasing the diversity of gene expression, and as a consequence of genetic changes. We, and others, have used antisense oligomers to manipulate both normal and aberrant splicing to alter the course of disease in animal models and in clinical studies. Antisense oligomers can suppress exon selection, or can anneal to splicing silencers to enhance inclusion of exons that are otherwise excluded as a consequence of poor exon definition. The most advanced antisense oligomer-mediated study at this time is an exon-skipping program using the morpholino oligomer, Eteplirsen to address frame-shifting deletions that flank exon 51 of the dystrophin gene. Such mutations cause the fatal X-linked muscle wasting disease, Duchenne muscular dystrophy. The majority of mutations causing this disease are deletions of one of more exons that disrupt the reading frame, and removal of flanking exon(s) during pre-mRNA processing can reframe the transcript, leading to translation of partially functional dystrophin. Similarly, targeted exclusion of selected exons bearing premature termination codons or indels, or those caused by cryptic splice site activation, can restore the open reading frame and dystrophin expression. An extended phase 2b clinical study has shown that exon skipping strategies can maintain ambulation and improve respiratory function in Duchenne muscular dystrophy patients, an outcome that is unprecedented in the history of this disease.
Epileptic encephalopathies (EEs) are characterized by severe, frequent seizures with a detrimental effect on development. The majority of EEs have a genetic basis, with significant genetic heterogeneity (>300 genes). A small subset are treatable. Rapid investigation of children with EE is mandatory to guide therapeutic choices and reproductive counseling. To date, the investigative process requires invasive neurometabolic procedures and financially prohibitive sequential genetic testing, with a low diagnostic yield (<10%). Nextgeneration-sequencing (NGS) provides a compelling tool to explore the genomic basis of undiagnosed EE. Recent literature has demonstrated the utility of NGS in epilepsy diagnostics with a diagnostic yield of up to 50%. However, many studies have a paucity of phenotypic information limiting genotype-phenotype correlations and clinical prognostication.
We investigated a cohort of children affected with infantile-onset EE, categorized by clinical and electrophysiological criteria. Whole exome sequencing was performed on 10 affected children using the HiSeq 2500 platform. We performed short read sequence alignment using BWA, and variant calling using the GATK HaplotypeCaller following best practices approaches. Potential causative variants were identified by a tiered approach: (1) comparison with a list of EE genes, (2) comparison of all potentially pathogenic variants with current literature, (3) trio analysis to identify de novo variants. Sanger sequencing was used to confirm candidate mutations. We identified pathogenic/likely pathogenic variants in 5 out of 10 children, including a variant in a newly described EE gene. This study highlights the importance of NGS in Mendelian disorders as a rapid diagnostic technique.
AACG Oral 2 COMPARATIVE HEATH ECONOMIC COSTINGS OF NEXT GENERATION SEQUENCING VERSUS TRADITIONAL NEUROMETABOLIC INVESTIGATION IN A COHORT OF CHILDREN WITH EPILEPTIC ENCEPHALOPATHY.
majority have a genetic basis, with several hundred genes known. The cost of the investigation of children with EE is immense as the results of neurometabolic and genetic disorders often display phenotypic overlap with other diseases. Numerous invasive investigations invariably include MRI scanning (with general anaesthesia), multiple EEGs, lumbar puncture for CSF metabolites and extensive serum/urine neurometabolic testing. Individual molecular genetic tests have a low sensitivity. Identifying specific gene mutations has been challenging until the advent of next generation sequencing (NGS). The current revolution in diagnostic molecular genetics through NGS now allows the testing of all genes in a cost-effective and timely fashion. We will investigate whether a genomic diagnostic approach to children with Epileptic Encephalopathy (EE) is a viable alternative to the traditional diagnostic algorithm. Design and Participants: A retrospective observational study of a cohort of 10 patients affected with EE has been performed. All patients have undergone the traditional neurometabolic investigative approach and were subsequently tested with NGS. With a health economist we have examined the cost-effectiveness of NGS to determine whether it is a viable, rapid, high-yield and a less expensive alternative to current sequential investigations. We propose, through these results, that NGS provides a comprehensive and more cost-effective management scheme for the investigation of EE. The fetal akinesia syndromes, severe congenital myopathies, and arthrogryposes are all heterogeneous disorders with prenatal or neonatal onset. Despite several causative genes being associated with these disorders, many cases remain without a genetic diagnosis. Next generation sequencing (NGS), can identify mutations in known and novel disease genes. Genomic DNA from individuals from 40 unrelated families with fetal akinesia, a severe congenital myopathy or arthrogryposis, was subjected to NGS with the aim of identifying the genetic cause of disease. Individuals were subjected to either whole exome sequencing or a custom-designed supercapture array, consisting of 277 known neuromuscular disease genes. Variants fitting the phenotype and inheritance pattern were investigated, and confirmed using Sanger sequencing. Analysis of NGS data resulted in a genetic diagnosis for 17/40 families, including 3/14 affected by a fetal akinesia syndrome, 9/15 by a severe congenital myopathy, and 5 of 11 with arthrogryposis. Mutations were identified in eight different known neuromuscular disease genes (CHRND, CHRNG, ECEL1, GBE1, MTM1, MYH3, NEB, and RYR1) and three novel neuromuscular disease genes (KLHL40, KLHL41, and Gene X). In conclusion, the use of NGS on a cohort of families with fetal akinesia, a severe congenital myopathy or arthrogryposis resulted in a diagnosis in 42% of cases. This study highlights the capabilities of NGS in determining the genetic diagnosis in heterogeneous diseases, as well as the ability to identify novel disease genes. Finally, this study has expanded the genotype-phenotype correlations for known neuromuscular disease genes. This project will explore the experience of peer support with the group members and their views and attitudes. Important concepts under consideration will be why the group has lasted for such a long time, the impact of shared ethnicity, what role the members felt the support group has played in their dealing with their mutation status and how it has influenced their decision making. From this we aim to identify factors that have contributed to the longevity and perceived success of this particular group, as well as the disadvantages, in order to guide the establishment of future support groups. We seek to study why this group has been successful and how this success can be replicated in other support groups. These results will then be used as a basis for further care and research, specifically in the development and evaluation of a future support group, to be formed in 2014/2015. We offer this test in a private genetic counseling setting where patients pay a standard fee for a consultation and then pay for any additional pathology directly to the pathology provider.
AACG Oral 3 NEXT GENERATION SEQUENCING PROVIDES ANSWERS FOR FAMILIES AFFECTED BY FOETAL AKINESIA, ARTHROGRYPOSIS, AND SEVERE CONGENITAL MYOPATHIES
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In our first 26 patients who requested Counsyl testing, we identified 13 carriers. Two were carriers for two conditions. There was one test that failed. One couple were suspected to be epidermolysis bullosa carriers and this was confirmed; one couple were hypothesized to be Connexin 26 carriers and this was also confirmed.
In a series of vignettes, we will highlight the genetic counseling challenges of offering the Counsyl Universal Genetic Test and reflect on the demographics and motivations of patients requesting this test. All patients had a heightened awareness of the risk of having a child with a disability, and saw the Counsyl test as a way to mitigate this risk. Women living with disorders of sex development (DSD) may have both complex genetic differences and gynaecological features which have an impact on their reproductive health. These differences can also impact on fertility, body image, self-esteem and social acceptance. This qualitative study aimed to explore the psychosocial support needs of women who have a DSD. Ten semi-structured interviews were conducted with women diagnosed with a DSD aged between 21 to 34 years. Participants were asked to discuss their wishes, needs and expectations of support services. Interviews were audiotaped, transcribed verbatim and analysed using thematic analysis.
ASGC Oral 4 EXPLORING THE PSYCHOSOCIAL SUPPORT SERVICES FOR WOMEN WITH DIVERGENCE OF SEX DEVELOPMENT
Findings revealed that overall participants felt satisfied with the available support systems, chiefly family support. However, social acceptance, formation of intimate relationships, coping with the physical implications, understanding reproductive options and maintaining better health outcomes were identified by participants as issues that could be improved with psychosocial support. Professional psychosocial and peer support services were identified as essential components of condition management and participants felt these should be offered as part of standard care practice. The majority of participants highlighted the value of appropriate peer relationships and wanted more support in this area. Participants recommended the development and provision of a resource inclusive of up-to-date health information, advice on fertility pathways, and contact information for both medical, psychosocial and peer support. We previously reported sequencing ∼1000 genes encoding the known mitochondrial proteome in 42 infants with definite biochemical OXPHOS disorders (Calvo et al., 2012 Sci Trans Med 4:118ra10) . In addition to proven diagnoses, this identified mutations in a number of candidate disease genes. A patient with deficiency of complexes I, II and III in muscle and liver had a homozygous mutation (c.203G>T, p.R68L) in LYRM4, encoding the ISD11 protein. ISD11 forms a complex with the sulfur donor NFS1 and stabilizes it. Complexes I, II and III rely on iron sulfur (Fe-S) clusters for enzyme activity. Sanger sequencing identified the same mutation in his similarly affected cousin, who had a more severe phenotype, died in the neonatal period and had deficiency of Complex IV in addition to Complexes I, II and III defects. Other Fe-S proteins were also affected in both patients, including the aconitases and ferrochelatase. Mutant ISD11 only partially complemented for an ISD11 deletion in yeast. In vitro studies showed that the L-cysteine desulfurase activity of NFS1 was barely present when co-expressed with mutant ISD11. LYRM4 mutations cause a novel defect in an early step of Fe-S cluster assembly, affecting a broad variety of Fe-S proteins. The differences in biochemical and clinical features between the two patients may relate to limited availability of cysteine in the newborn period and suggest a potential approach to therapy. The purpose of this report is to describe an atypical, severe presentation of glycogen storage disease (GSD) IXa and the aggressive dietary management used to dramatically improve metabolic control. GSD IXa (resulting from PHKA2 mutations) has been widely regarded as a benign condition that does not warrant treatment because the childhood symptoms frequently improve with age. The implementation of next-generation sequencing in diagnostic laboratories around the country is promising to improve the costeffectiveness of genetic testing and the diagnostic pick-up rate. A number of technology platforms and sequencing strategies are available, ranging from targeted gene panels to whole-exome and wholegenome sequencing. As part of our service development we have been assessing the benefits of different sequencing approaches for application in inherited disorders, cardiomyopathies, familial cancer, somatic mutation detection in tumors and pediatrics. These applications differ in the number of known disease-associated genes, clinically actionable genes, the pick-up rate of existing methods and the sensitivity of detection required. We describe strategies we have employed to choose technology platforms for new test development. Current efforts are concentrating on the validation of new tests and we give examples of our efforts to examine the accuracy and sensitivity of detection. Finally, when expanding our gene-testing service we have encountered challenges in managing the annotation and clinical interpretation of genomic variants. We describe some of the resources and tools we have examined. Finally, as with any new technology, successful clinical implementation depends largely on the successful integration into the clinical management of patients; having chosen the 'right' group of disorders and genes to test after consultation with the key clinical end users and managing clinician information and patient consent and developing appropriate reporting formats. It is an exciting time in medical genetic testing with new technologies and new tests continuously advancing the scope of our services.
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ASIEM Oral 1 MUTATIONS IN LYRM4, ENCODING IRON-SULFUR CLUSTER BIOGENESIS FACTOR ISD11, CAUSE DEFICIENCY OF MULTIPLE RESPIRATORY CHAIN COMPLEXES
ASIEM Oral 2 WHOLE EXOME SEQUENCING CONFIRMS LEIGH SYNDROME IN A PATIENT SHOWING LITTLE BIOCHEMICAL EVIDENCE OF A MITOCHONDRIAL DISORDER
Next generation sequencing technologies are proving to be powerful tools in the identification of genetic variants underlying rare genetic disorders. Our laboratory has undertaken whole exome sequencing (WES) and whole genome sequencing (WGS) on a number of cases of perinatal death (PD). PD is defined as the death of a fetus after a pregnancy of at least 20 weeks gestation or weighing 400 g, or of a neonate within 28 days of birth. At present, the autopsy of PD requires a complex investigation involving medical imaging, laboratory investigations, and the examination of the body and placenta. Despite such careful process, a cause may not be found in approximately 22% of cases. We hypothesized that WES or WGS would act as a 'genetic autopsy', providing an explanation for many cases of PD and improving the definitive diagnostic yield. We also expected to identify novel monogenic disease genes with functions critical in embryonic developmental pathways. The validity of this approach was first demonstrated using WES to identify a novel homozygous variant in FGFR2 causing neonatal lethality in a fetus from consanguineous parents. WGS has been applied to unexplained polycystic kidney disease (PKD) in two fetuses from consanguineous parents, found to share three regions of homozygosity (ROH). No known PKD genes were located within their ROH. WGS and analysis of ROH has identified only 1 outstanding candidate gene. Segregation analysis and primary functional assays are being performed to assess pathogenicity. We report the data from the first known Renal Genetics MDT clinical service in Australia, attended by a Clinical Geneticist and Nephrologist. Since August 2013, 30 patients have been seen in the clinic based on referral type: (a) known genetic kidney disease (GKD) -disease information/genetic counseling (11), (b) suspected GKD with a family history -diagnostics (9), or (c) suspected GKD without a family history -diagnostics (10). Referrals were from nephrologists (14), medical specialists (2), and GPs (14). Diagnostic categories included: ADPKD (8), non-ADPKD renal cysts (7), nephropathy (6), metabolic (2), syndromic (3), and unknown cause for renal failure (4). All patients were given information on the diagnosis or differential diagnoses. We delineated a family history in 16 patients (53%). Genetic counseling was provided to 21 patients (70%). Genetic tests were ordered in 14 patients (47%), indications being: a) diagnostic (14%), genetic counseling (14%), or both (72%). Of these, 3 have positive results and 11 are pending. Other non-genetic investigations (imaging/urinary studies) were ordered in 6 (20%) patients for diagnostics.
So far the successful outcomes of the clinic have been: (a) disease information and genetic counseling in one clinic appointment for 21 patients, (b) new clinical diagnoses in 2 patients, (c) new clinical and molecular diagnoses in 2 patients, and (d) molecular confirmation of a clinical diagnosis for genetic counseling in 1 patient. The positive experiences of this clinic model highlight the need for mainstreaming genetics services and the development of similar clinics in locations across Australia. Based on our experience, three key elements required for successful population-based detection of LS in Australia will be discussed. We propose the adoption of a coordinated approach at a national level that includes the above key elements. This endeavour is a priority of the recently established Inherited Cancer Connect Partnership (ICCon), a group of clinicians and scientists focused on improving the outcomes of people with rare inherited cancer syndromes. Microphthalmia and coloboma are rare genetic conditions that may be associated with other ocular malformations including anophthalmia, anterior segment dysgenesis and cataracts. Disease genes include SOX2, OTX2, CHX10, BMP4 and RAX, but in many patients the disease gene is not known. In addition to the low mutation detection rate for patients with these conditions, there is often low penetrance and variable expression which may be due to the presence of genetic modifiers. WNT signalling is important in various developmental processes, including eye development. We sequenced a candidate gene in the WNT signalling pathway in a cohort of 180 patients with cataract/microcornea, coloboma/microphthalmia and Peters anomaly conditions, revealing 3 novel mutations in 5 probands. Additional next-generation sequencing in the 5 patients did not reveal any mutations in the known disease genes. The mutations were subjected to luciferase assay using the TOPFLASH reporter system. One mutation resulted in a significant difference in WNT activity. To further evaluate the candidate gene in early eye development we generated a mutant mouse line with variable WNT activity regulated by the dosage of the candidate gene. Subsequent examination of the morphology and markers of neuroretinal, retinal pigment epithelium (RPE) and lens development of the generated mouse mutants revealed regionalization of WNT signalling activity. We also noticed reduced expression of the neuroretinal marker Chx10 and ectopic expression of the RPE marker Mitf in the mutant mouse line. Our results demonstrate the key function of WNT signalling in precise spatial and temporal in early eye development. Common reasons for testing below the cut-off were: no contact with family, small family size, family history of breast and ovarian cancer, epithelial ovarian cancer and triple negative breast cancer pathology. Further analysis of exception cases showed that 13/65 cases of ovarian cancer and 27/92 cases of grade 3 triple negative breast cancer did not meet MMS testing criteria. 1 (7.7%) and 2 (7.4%) mutations respectively were found in these groups. Increasing the minimum MMS testing cut-off from ≥ 15 to ≥ 16, saw no decline in the sensitivity, but a slight improvement in specificity of finding a BRCA mutation. Few mutations were missed using the MMS. Testing exception cases may result in over testing, increased economic burden and psychosocial issues for patients without improved mutation detection rates. Smith-Lemli-Opitz (SLO) syndrome is an autosomal recessive disorder of cholesterol synthesis due to deficiency in 7-dehydrocholesterol (7-DHC) reductase. SLO is associated with specific dysmorphology, microcephaly, syndactyly, cleft palate, growth retardation, genital ambiguity and intellectual disability with autistic features. The autistic features may respond to cholesterol supplementation. Increased levels of 7-DHC are a marker for SLO and routinely used for testing of autistic children. A total of 6 years of requests for 7-dehydrocholesterol (7-DHC) testing at SA Pathology were audited audio-recorded consultations (n = 32), parent pre-consultation surveys (n = 32), and post-consultation interviews with parents (n = 32) and clinicians (n = 11). Content, thematic and discourse analyses were completed across the data sets. Results: While the content of consultation was similar, different communication 'styles' were apparent and variable approaches were used when explaining genetic results. Interviews with parents revealed that overwhelmingly, they appreciated and were reassured by the consultation. The vast majority reported a positive relationship with their clinician and felt the genetic information had been explained in a very useful manner. During interviews, clinicians reported many professional challenges working in this area, both practical and emotional, especially frustrations of being unable to answer parents' questions regarding the cause of the child's delay. Conclusion: Detailed analyses of three complementary data sources provided rigorous and unique perspectives on impacts regarding the introduction of new genetic technologies for clinicians and parents. Findings from this study will inform best practice in this area of medical communication. The aim of this study was to understand parents' experiences of an uncertain chromosomal microarray (CMA) result for their child. This research utilized a qualitative approach with a phenomenological theoretical perspective. Families were ascertained via the Victorian Clinical Genetics Services and all families had a child with 16p11.2 or 15q13.3 microdeletion. Semi-structured interviews were conducted with nine parents of eight children aged between 2 and 11 years old at the time of testing. Interviews were transcribed verbatim and thematic analysis was used to identify themes within the data. Participants were unprepared for the CMA test and accompanying abnormal result. Despite a complex perception of the extent of their child's condition and a mixed understanding of the clinical relevance of the result, they were accepting of the limitations of current medical knowledge, and appeared to have readily adapted to the result. The test result was empowering for parents in terms of access to medical, educational and financial services; however, they articulated significant unmet support needs. Participants expressed hope for the future, in particular that more information would become available over time, and were open to the possibility of further testing for their child. This research has demonstrated that parents of children who have an uncertain CMA result appear to adapt to uncertainty and limited available information. Furthermore, parents valued honesty and empathic ongoing support from health professionals despite limited information. Genetic health professionals are well positioned to provide such support, aid families' adaptation to their situation and promote empowerment. This study aimed to explore the experiences of parents raising a child with an undiagnosed medical condition by: describing parental uncertainty; assessing the role of hope, social support and illness cognition in adaptation; and exploring parents' satisfaction with support services available. Previous studies have shown parents in this population have to cope and adapt to living with high levels of uncertainty. This uncertainty permeates many aspects of parents' lives and imposes challenges when making short and long-term plans. Data was collected through an online survey. Recruitment occurred via support groups and online parenting forums, and 51 responses were included in the analysis. Data analysis suggested that in this population parents appraised uncertainty as a threat. Uncertainty was not identified as having a significant association to any domains of adaptation. Multivariate analysis identified a number of significant associations between key variables and domains of adaptation, with perceived benefits of the child's illness having the strongest association. Parents believed there were significant gaps in the support received, with many believing additional support services would be available if their child was diagnosed. The majority of parents believed a diagnosis was of high importance, and this not associated with the length of time without a diagnosis. This study provided insight into the challenges parents face when raising a child with an undiagnosed medical condition. It is important for genetic health professionals to be aware of these factors as this will enhance their ability to support their clients and implement strategies to facilitate adaptation. Due to advancing genetic technologies, carrier screening for multiple inherited conditions can now be offered within the population. This research aimed to explore how women experience undergoing carrier screening for three common inherited conditions: cystic fibrosis (CF), spinal muscular atrophy (SMA) and fragile X syndrome (FXS), through the Victorian Clinical Genetics Services (VCGS) Reproductive Genetic Carrier Screening (RGCS) program. Adopting a qualitative approach using phenomenology as the theoretical framework, the study utilized in-depth semi-structured interviews, which were transcribed verbatim. The transcripts were coded using thematic analysis to identify emerging themes. Eight female participants took part in this study: five received a carrier result for SMA and three for CF. The majority of participants were pregnant during screening and described the decision to have the test as straightforward. Participants experienced emotional responses such as anxiety and stress whilst waiting for their partner's test result and also completed online research to find out more about the relevant condition during this time. Participants supported population carrier screening, preferably offered prior to conception. The findings of this study confirmed that genetic counselors (GCs) play an essential role within this program by providing support to couples after they receive a carrier result, particularly given the varying consent processes undertaken prior to screening. The provision of suitable Internet resources and GC-facilitated guidance to access reliable information would empower couples and assist the coping process. Improving awareness of the availability of population carrier screening within the community will also help improve knowledge levels and facilitate preconception screening. The Osteogenesis Imperfecta syndromes, also known as 'Brittle Bone' group of genetic skeletal disorders, result from mutations in over 18 distinct genes loci. In 2010, the International Nosology Committee (INCDS) grouped the phenotypes arising from these mutations into 5 major groups (Osteogenesis Imperfecta types 1-5). With the exception of OI type 5, each group shows further heterogeneity. For this reason the INCDS recommended the use of a phenotypic classification. The phenotypic heterogeneity reflects the effect of the type of mutation (nonsense, missense, splicing, deletion/insertion, frameshift), the position of the mutation in the translated polypeptide and the effect on folding and functional activity of the protein as well as its trafficking from the cell. There are still as yet unexplained mechanisms which result in wide expressivity. There is both allelic heterogeneity (mutations in the two genes COL1A1 and COL1A2 genes result in at least 4 phenotypes) and allelic heterogeneity (at least 18 distinct gene loci). The phenotypic consequences of mutations in 4 of these genes may segregate in an autosomal dominant mode and 2 of these genes in an X-linked recessive mode. We have developed counseling paradigms for these 5 phenotypic groups and used these to guide genetic counseling for these 'disorders'. We have used these paradigms to counsel new and former patients. There is a high acceptability for the concept of preimplantation genetic diagnosis PGD in dominantly inherited disorders among young people with OI.
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ASGC Oral 6 IT WASN'T A DISASTER OR ANYTHING: PARENTS' EXPERIENCES OF THEIR CHILD'S UNCERTAIN CHROMOSOMAL MICROARRAY RESULT
ASGC Oral 7 LIVING WITH UNCERTAINTY: THE ROLE OF HOPE, SOCIAL SUPPORT AND ILLNESS COGNITION IN RAISING A CHILD WITH AN UNDIAGNOSED MEDICAL CONDITION.
ASGC Oral 8 POPULATION GENETIC CARRIER SCREENING FOR CYSTIC FIBROSIS, FRAGILE X SYNDROME AND SPINAL MUSCULAR ATROPHY: EXPLORING EXPERIENCES OF CARRIERS IDENTIFIED THROUGH THE VCGS REPRODUCTIVE GENETIC CARRIER SCREENING PROGRAM
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ASGC Oral 10 BEGINNING A GENETIC COUNSELING SERVICE IN A PRIVATE OBSTETRIC ULTRASOUND PRACTICE
Alice Weeks
Specialist Women's Ultrasound, Melbourne, VIC Australia
Genetic counseling employment has traditionally been based in public hospitals. There is, however, an increasing number of genetic counselors working in private settings. The changing face of genetic counseling practice includes the expansion of employment for genetic counselors, in particular, in private health care settings. Using case examples and clinical data, this presentation outlines the experience of setting up a successful prenatal genetic counseling service in a private obstetric ultrasound practice in Melbourne. Discussion of key professional issues and challenges includes the definition of a new role, supervision, certification, and the introduction of genetic counseling to external practitioners. The aim of this presentation is to challenge and encourage genetic counselors to seek alternative and new types of employment.
conduct research/study that is not possible in Australia. My study project was a 6-week scholarship to explore the practical management strategies to improve the quality of life of Australian children with genetic metabolic disorders. This journey commenced at the Willink Metabolic Unit,Manchester Children's Hospital, (3 weeks) and The Royal Salford Hospital (1 week) before moving to London to visit Evelina Children's Hospital and Great Ormond Street Hospital (1 week) with the final week attending the International Congress of Inborn Errors of Metabolism in Barcelona. Key areas identified for consideration in our metabolic unit are: (1) A lifetime metabolic service, (2) a two-staged transition to adult services, (3) an effective model for enzyme replacement therapy in the home and (4) a model for delivery of respite and palliative care in the hospice setting. This experience increased my professional knowledge in these areas and resulted in a report to health administrators in how service delivery can be delivered by different models of care that may present both improvement and cost savings. Background: GSD1b is associated with significant morbidity, namely hypoglycaemia, lactic acidosis, hepatomegaly, neutropenia, recurrent infections, mouth ulcers, arthritis, hyperuricaemia, hyperlipidaemia, and inflammatory bowel disease (IBD). Complications may include osteoporosis and hepatic tumors with potential for malignant transformation. Liver transplantation (LT) in GSD1b treats the underlying defect, many of the clinical and biochemical manifestations and the hepatic malignancy risk. Cases: Two patients with GSD1b aged sixteen years have undergone deceased donor orthotopic LT. Both had required GCSF for neutropenia and gastrostomy insertion for nutrition support. Case 1 had recurrent hypoglycaemia, intellectual disability, IBD with recurrent oesophageal strictures, requiring multiple dilatations and stenting, poor dentition, deafness and significant social issues. Case 2 had HLA B27 positive arthritis, IBD and recurrent mouth ulcers. Both cases required nutrition support using polymeric formula and uncooked cornstarch (UCCS) during the day, and overnight Case 1 UCCS boluses and Case 2 continuous polymeric formula with additional glucose polymer. Height and BMI were <0.4th and 91st centiles respectively for Case 1 and 0.4th and 75th centiles respectively for Case 2. Discussion: Both cases are doing well at 15 and 9 months post LT with improved quality of life and improved school attendance. GCSF requirement has decreased, both are enjoying eating and Case 1 is swallowing well without oesophageal structuring. Case 2 now has quiescent arthritis. IBD appears to have significantly improved in both cases. Case 1 has normalized BMI (50th centile). Thus LT is associated with excellent outcomes for patients with significant morbidity related to GSD1b. Aim: Tetrahydrobiopterin (BH4) is a relatively new treatment option for patients with Phenylketonuria (PKU). Funding was obtained by ASIEM Dietitians to develop a guideline and education package for the implementation and management of BH4 therapy for PKU in Australasia. Process: (1) A guideline development group was formed; (2) project officer recruited; (3) guideline scope agreed; (4) stakeholders identified: patients/carers of people with PKU and health professionals involved in PKU management in Australasia; (5) clinically relevant questions formed; (6) extensive literature review completed and appraised; (7) international survey to 'BH4 experts' undertaken to capture practical day-to-day experience not reported in the literature; (8) specifically designed Delphi Survey for health professionals developed to formally address issues either inadequately addressed in the literature or had evidence that could lead to contradictory recommendations and to explore issues relevant to our population and clinical setting; (9) telephone survey for PKU patients/carers to ensure patient/carer needs considered; (10) interstate ethics approval gained. The Delphi Survey was sent to 54 health professionals including clinicians, dietitians, nurses, social workers and psychologists involved in Australasian PKU management. Two rounds were completed with consensus reached on any statement with ≥75% agreement. The telephone survey was completed with patients/carers in Queensland, Victoria and New South Wales with representation across patient groups to identify areas of concern and education requirements related to the introduction of BH4 therapy. Outcome: The results will be used to develop the guideline and education package for dissemination and implementation as appropriate across Australasia. A female infant was diagnosed with carnitine-acylcarnitine translocase (CACT) deficiency following hypoglycaemia, hyperammonia, severe cardiac dysfunction and seizures in the first week of life. She was discharged home on day 23 on a low fat diet (5% total energy from long chain fat) with total energy intake of 160kcals/kg/day from modified fat formula and glucose polymer, 4-hourly feeds with no fasting, supplementary beta-hydroxybutyrate (600mg/kg/d) and carnitine. She is now 4 years old and developing normally, with growth on the 50th centile. When well she eats age-appropriate foods supplemented with MCT, relying on a bottle for a high daily oral intake of formula. Education on appropriate food choices has been well understood and a gastrostomy was sited at 9 months of age for use when oral intake is poor and overnight feeds. She has a history of recurrent viral infections, with each episode life threatening, some with hypoglycemia, some with bradycardia. Dietetic challenges centre around achieving her high energy needs (2 x requirement at 180-200 Kcals/kg/day, with no evidence of malabsorption) using less than <8% LCT, when well and unwell whilst maintaining balanced eating habits. Other challenges include distance from primary metabolic team with acute local hospital management. NIPT was first commercialized in 2011, with screening offered for the detection of trisomy 21. There are now 5 commercial companies offering NIPT and the range of trisomies screened has been expanded to include 13,18 and 21, with some companies offering sex chromosome abnormalities as well as triploidy. Twin screening remains to be conclusively validated. NIPT uses the fragments of fetal placental DNA circulating in the maternal plasma, referred to as the fetal fraction (ff).ff shows inter-patient variation, but generally increases with gestational age. ff is affected by maternal BMI; with a greater maternal circulating volume, the lower the fetal fraction and the more difficult a diagnosis becomes, depending on the test methodology. There are 2 main methodologies employed in NIPT, a counting method, which does not distinguish between maternal and fetal fragments in the maternal plasma and a SNP method which can distinguish between maternal and fetal fragments; this latter methodology also includes a paternal SNP screen. Maternal age in the group screened ranged from 25 to 44 years. The overall ff detected ranged from 1.2% to 23.9%. Results were obtained in a ff range of 3.3% to 23.9%. The gestational age at screening ranged from 9 to 19 weeks. Recollection, due to low ff was within the range predicted by the testing company; a result was more likely to obtained at a lower ff if a paternal DNA swab was submitted. Very elevated BMI cases failed to yield a result after recollection. Array technology has been used to routinely investigate fetal autopsy cases in our laboratory since March 2011. These autopsy cases involved fetuses that died in utero or fetuses terminated due to abnormal ultrasound findings. Array CGH investigation of autopsy cases showed the incidence of a causative copy number variant (CNV) was 4.7% (4/85). Since July 2013, SNP Array has been used to investigate 89 autopsy cases. Eleven CNVs were detected with six determined to be causative (6.7%).SNP array also detects regions of homozygosity (ROHs) which can guide future DNA sequencing effort to diagnose autosomal recessive (AR) disease. Seventeen cases (19%) were found to have at least one ROH. Case 1 is a fetus suspected to have AR Fraser syndrome. The SNP array detected 25 ROHs (207Mb, 6.9% of human genome). One ROH included the FRAS1 gene, one of the genes known to cause Fraser syndrome. Subsequent sequence analysis of the FRAS1 gene revealed a homozygous, pathogenic mutation 9525T>A. Cases 2 and 3 were siblings with polycystic kidney disease with no mutation of the PKHD2 gene. SNP array identified multiple ROHs in each fetus with 3 shared ROHs. Cases 4 and 5 were siblings with short ribbed polydactyly ?type IV with multiple ROHs and 3 shared ROHs. NGS is currently being conducted to identify AR mutations within the shared regions of ROHs. SNP array is a valuable tool for investigating fetal autopsy cases as CNVs, ROHs, isodisomy and mosaicism can be identified in a single test.
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ASoC Oral 7 CYTOGENETICS: BACK TO THE FUTURE!
Ling Sun, Lucy Gugasyan
Cytogenetics, Monash Pathology, Monash Health, Melbourne, VIC, Australia
Various cytogenetic techniques can be used in conjunction to diagnose a patient's karyotype. Here we describe how four different methods helped characterize the karyotype of a 66-year-old female patient presenting with secondary amenhorrhea and features of Turner syndrome. The initial investigation on G-banded metaphases showed an apparent terminal deletion of one X chromosome at band q22.1 in 50 cells. A molecular karyotype to further characterize this finding additionally showed a 0. Early-onset epileptic encephalopathies are severe disorders of cognitive, sensory and motor development. Genetic testing in this field is hampered by the highly heterogeneous nature of these disorders, with marked phenotypic variability, overlapping clinical features and the involvement of multiple genetic loci. Due to the high costs and long turn-around times, traditional methods of molecular diagnosis are usually limited to a small number of candidate genes. Massively parallel sequencing (MPS aka next generation sequencing) provides an ideal platform for improving the genetic diagnosis of these disorders, by allowing a large number of genes to be tested simultaneously at a relatively low cost. Three different targeting approaches (Illumina TruSeq Custom Amplicon, Agilent Haloplex Custom Target Enrichment and Illumina TruSight Exome) have been trialled to interrogate up to 53 genes associated with disorders of early-onset seizures, Rett syndrome, neuronal ceroid lipofuscinoses or other disorders with overlapping clinical features. All three methods successfully identified candidate disease-causing variants in our patient cohort, but coverage performance varied depending on the method of targeting. Pick-up rate for patients screened for epileptic encephalopathy genes is low, with the majority of positive findings made in patients whose specific diagnoses were identified by other strong pointers (e.g., enzyme assays or characteristic clinical presentation). Cascade testing of other family members was important in the interpretation of variants of uncertain significance. The introduction of MPS into diagnostic laboratories has greatly facilitated the genetic diagnosis in patients with epileptic encephalopathy by reducing the time and cost required for testing.
MGSA Oral 7 EXOME SEQUENCING IN MOTORNEURONE DISEASE/ SPINAL MUSCULAR ATROPHY: IMPROVED DIAGNOSTICS AND COST-EFFECTIVENESS
Familial cases of haematopoietic malignancy (HM) offer the opportunity to identify novel predisposition genes that likely also impact on the more common sporadic cases. They also offer affected families a tool for screening for predisposed individuals and possibilities for treatment if the identified genes or mutations are druggable. We previously discovered GATA2 as a myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) predisposing gene which has led to the identification of ∼50 families worldwide with GATA2-related disease, and a recommended standard of care for carrier individuals who develop disease.
We have performed whole exome sequencing (WES) and/or AmpliSeq 29 gene MDS/AML panel sequencing on the Ion Proton on affected and unaffected members from 50 families predisposed to HM. To date, we have sequenced over 200 samples and have not only developed a pipeline for sequence generation, alignment and variant calling (including detection of low frequency variants to assess clonal expansion), but also for variant annotation to facilitate pathogenicity calling. We have used the power of this approach to identify new germline mutations, to follow the mutational progression of disease through therapy, remission and relapse, and to identify pathogenic initiator or driver mutations in individuals prior to the onset of symptoms. This helps catalogue markers for early diagnosis of disease onset, contributes to prognostic data, enables time for development of therapeutic approaches including searching for bone marrow donors, and adds to understanding the biology of genes and genetic interactions that are common in HMs and those that unique to specific HMs. SciWriting, Magill, SA, Australia (www.writeresearch.com.au) This 90-minute workshop aims to help conference presenters take the next steps in moving their conference presentation towards an article likely to get a respectful reading from the editors and referees of their target journal. It is based on the presenter's recent teaching text on this topic, and reflects 20 years' experience in helping researchers write science effectively. Participants should bring with them a paper copy of a research article relevant to their own field and published in a journal they would like to target -we will analyse aspects of these during the workshop. Topics to be addressed during the workshop include: (1) Developing article writing skills by analysing articles using applied linguistics frameworks; (2) Results as 'driver': developing and writing your 'take-home message' and selecting a target journal; (3) Article structures and referee criteria -the connections; (5) Introductions: 5 'stages' to a compelling justification. Mutations in LARS2 have previously been associated with Perrault syndrome (premature ovarian failure and hearing loss). LARS2 encodes mitochondrial leucyl-tRNA synthetase which is required for mitochondrial protein synthesis. In this study we report LARS2 variations associated with a severe multisystem disorder. The proband was born prematurely (27 weeks) with severe lactic acidosis, hydrops and sideroblastic anaemia. She had multi-system complications with hyaline membrane disease, impaired cardiac function, a coagulopathy, pulmonary hypertension, progressive renal disease, and succumbed at 5 days of age. Whole exome sequencing was undertaken to identify a genetic diagnosis, and functional studies performed to investigate pathogenesis. Whole exome sequencing of patient DNA revealed compound heterozygous mutations in LARS2 (c.1289C>T; p.Ala430Val and c.1565C>A; p.Thr522Asn). The 5 enzyme complexes of mitochondrial oxidative phosphorylation (OXPHOS) comprize a total of more than 80 subunits but most patients with single enzyme defects lack mutations in these subunits. We used massively parallel sequencing (MPS) of patients to identify two novel OPXHOS assembly factors and proved causality via lentiviral correction studies in patient fibroblasts. First, we identified a homozygous splicing mutation in the C6orf125 gene (now renamed UQCC2) in a consanguineous Lebanese patient with complex III deficiency, severe intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction. Sequence-profile based orthology prediction shows UQCC2 is an ortholog of the Saccharomyces cerevisiae complex III assembly factor, Cbp6p, although its sequence has diverged substantially. UQCC2 interacts with UQCC1, the predicted ortholog of the Cbp6p binding partner Cbp3p, and both are required for synthesis &/or assembly of the mtDNA-encoded cytochrome b. Second, we studied eight complex IV-deficient patients with Leigh syndrome from six families of Lebanese origin. Complementation analysis suggested they had mutation(s) in the same gene but targeted MPS of 1,034 genes encoding known mitochondrial proteins failed to identify a likely candidate. Targeted MPS of a linkage region on chromosome 19 identified a homozygous mutation (c.3G>C, p.Met1?) in C19orf79 (now renamed PET100). We showed it is located in the mitochondrial inner membrane and forms a ∼300-kDa subcomplex with complex IV subunits. We estimated that the mutation arose at least 520 years ago, explaining how the families could have different religions and different geographic origins within Lebanon. GADD45A is a tumor suppressor gene that plays cell-type dependent roles in cellular stress co-ordinating DNA repair and de-methylation, cell cycle arrest, and pro-apoptotic or pro-survival responses. Methylation of four discrete CpG (CpG1-4) residues in the distal promoter of GADD45A is a hallmark of many solid tumors and has been associated with impaired cell stress signaling and reduced drug response. In AML, GADD45A silencing is widespread but poorly characterized. We have shown that hypermethylation of the distal promoter of GADD45A (CpG1-4) is a common event in AML, occuring in 93 of 222 (42%) patients. GADD45A hypermethylation is associated with poor survival in AML overall (median OS: 10 vs 25mths; p = .03) and in the intermediate group of patients (median OS: 11 vs 33mths; p = .04). The association of GADD45A hypermethylation with poor overall survival was also validated in an independent patient cohort. Subsequent exome capture and Sequenom-based mutation screening has revealed a striking overlap between GADD45A hypermethylation and IDH1/2 and TET2 mutations (78%; p < .0001). This co-association suggests that GADD45A may be a key functional target of the DNA demethylation pathway governed by IDH1/2 and TET2. Consistent with this, we show in patients and AML cell lines that re-activation of GADD45A can be achieved through treatment with mutant IDH inhibitors and the hypomethylating agents including Decitabine, resulting in increased chemosensitivity to Daunorubicin. In summary, GADD45A promoter hypermethylation is a novel functional biomarker of outcome in AML and its silencing is critical to chemoresistance.
Congenital cataracts have a significant impact on visual acuity and are responsible for 10% of childhood blindness worldwide. Congenital cataracts can also be associated with other ocular abnormalities such as glaucoma, microphthalmia and anterior segment dysgenesis, as well as genetic and metabolic syndromes. Cataract-microcornea is a genetically heterogeneous condition with over 30 known genes responsible. This study applied a targeted next-generation sequencing approach to an Australian cohort of 40 probands with cataracts +/-microcornea, targeting 32 cataract-associated genes. Both the Illumina Truseq custom amplicon and Illumina Trusight Clinical Exome approaches were used. This study demonstrates the power of targeted next generation sequencing for an accurate diagnosis, and its effect on management and prognosis. 31 variants of interest were found in 29/40 (72%) of families, 21 of these were novel variants. Further segregation analysis confirmed likely mutations in 23/40 families (57.5%), in 13 genes. Half the mutations were found in the cataract-associated crystallin genes. In 2 families, mutations were found in the X-linked syndromal gene NHS, which refined the diagnosis and had important intellectual development and family planning implications. Mutations were also found in the aniridia-associated gene PAX6 in 2 families, broadening the phenotypic features of this gene and altering the patient's management and monitoring. This study also adds to our knowledge and understanding of mutations in rarely reported lens-associated genes such as MIP, VIM and MAF. Our study demonstrates the many benefits of targeted next generation sequencing, which we will continue to explore in other developmental eye disorders and retinopathies. Massively parallel sequencing (MPS, aka next generation sequencing) is a powerful tool for diagnostic genetic medicine, decreasing the time and cost required for testing a large number of genes associated with overlapping phenotypes. For Mendelian disorders with a limited number of causative genes, disease-targeted gene panels may have greater clinical utility over whole exome or whole genome sequencing, by allowing greater depth of sequencing coverage and reducing the complexity of variant interpretation. On the other hand, the design and validation of a panel for every disorder of interest are both cost and time-prohibitive, especially when discovery of new candidate genes entails constant revision of the panel with each addition. Using the Illumina TruSight panels (Inherited Disorders, Exome and One), we defined a variety of disease panels focusing on genes with known clinical phenotypes. Sequencing at average read depth of 300x provided over 97% coverage over the entire panel. Point mutations and medium sized insertions and deletions (10-50 bp) were identified, providing genotype diagnoses in patients with an aortopathy, epileptic encephalopathy, developmental eye disorders, mitochondrial disorders, renal disorders, osteogenesis imperfecta, Fanconi anemia, autoinflammatory disorders and various metabolic disorders. TruSight panels represent a versatile option for screening genes associated with a wide range of different clinical phenotypes with the use of a single test method. Not only does this reduce the time and expense of testing, it allows for greater flexibility in reviewing subpanels of genes, maximizing coverage over genes of interest, and minimizing incidental findings.
Oral 8 USING TRUSIGHT PANELS TO CREATE DISEASE-SPECIFIC GENE PANELS FOR MASSIVELY PARALLEL SEQUENCING TESTING
Two problems for molecular diagnosis of neurogenetic disorders are high levels of genetic heterogeneity and involvement of large genes; for example, titin. These problems result in many patients not being diagnosed by current Sanger-sequencing based diagnostics. To offset these problems we have developed a TargetSeq (Life Technologies) capture panel consisting of 335 disease genes with mutations detectable by next generation sequencing (NGS). The genes were 276 neurogenetic and 59 cardiomyopathy genes, targeted together because of clinical overlap. The 335 panel genes were captured from pools of 16 bar-coded patient DNA samples and sequenced 16 patients at a time using Ion Proton TM (Life Technologies) sequencing. Variant analysis was by either custom Annovar or Cartagenia (Cartagenia, Inc.) based pipelines. Testing the panel identified 88% of the known small-scale mutations in 28 positive controls. Known mutations deliberately chosen in regions not sequenced well by NGS were not detected. Using the FishingCNV package, we identified 90% of CNV controls, including 100% of CMT1A/HNPP duplication/deletion controls. Although one single exon CNV was detected, not all small CNVs were detected. We have screened >300 molecularly undiagnosed probands, identifying mutations in 59 disease genes, many of which were not previously analysed by the diagnostic laboratory due to Sanger sequencing costs. Using the targeted panel is not ethically different to traditional sequential Sanger sequencing diagnostics. The panel needs updating regularly with new disease gene discoveries. We now receive samples from all round Australasia for analysis of the 335-gene panel, which is cheaper than Sanger-based analysis of one medium-sized gene. We recently discovered a non-coding regulatory change in HCFC1 that associated with X-linked intellectual disability (XLID) in a large multigenerational family (MRX3). The single base change abolished binding of the YY1 transcription factor at a highly conserved sequence in the 5'UTR of HCFC1, resulting in loss of HCFC1 transcriptional repression. We employed ex-vivo models of embryonic neural development to show that this change was likely pathogenic; overexpression of HCFC1 caused cell cycle exit of neural progenitor cells (NPCs), and reductions in neurite growth of hippocampal neurons. Intriguingly, loss-of-function HCFC1 mutations have now also been reported to cause severe neurodevelopmental delay. We have identified four additional non-recurrent missense variants in HCFC1 that segregate (where evidence is available) with ID in four families, and sought functional validation of pathogenicity. HCFC1 is a modular protein that harbors transcriptional activation and repressive activities, and mutations may manifest as either gain or loss of function. We investigated the effects of both loss-and mutation-of HCFC1 function on the behavior of neural cells using ex-vivo assays. In contrast to over-expression, reduced Hcfc1 expression promoted the cell cycling of NPCs at the expense of differentiation, and enhanced neurite growth of neurons. All four variants were tested for their ability to affect neurite growth when overexpressed in wildtype neurons, and in neurons depleted of endogenous Hcfc1. Our work supplies information on the pathogenicity of HCFC1 variants found in patients with ID, and identifies relevant disease mechanisms that converge on cells present during embryonic stages of brain development.
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Oral 11 HCFC1 GAIN-AND LOSS-OF-FUNCTION MUTATIONS CAUSE NEURODEVELOPMENTAL DISORDERS, AND AFFECT NEURAL PROGENITOR CELL BEHAVIOR AND NEURONAL GROWTH.
